Annual report pursuant to Section 13 and 15(d)

Consolidated Statements of Cash Flows

v2.4.0.6
Consolidated Statements of Cash Flows (USD $)
In Thousands, unless otherwise specified
12 Months Ended
Dec. 31, 2012
Dec. 31, 2011
Dec. 31, 2010
Operating activities:      
Net loss $ (30,857) $ (16,550) $ (8,541)
Adjustments to reconcile net loss to net cash used in operating activities:      
Amortization of intangible assets 3,509 3,716 1,063
Depreciation and amortization of property and equipment 8,908 7,755 7,246
Revaluation of redeemable convertible preferred stock warrant liability 0 0 677
Loss on disposal of property and equipment 1,551 49 148
Impairment of marketable securities 753 0 0
Extinguishment of royalty payable 0 0 461
Gain from extinguishment of asset retirement obligation (212) (124) 0
Stock-based compensation 5,076 9,431 8,737
Common stock issuances for royalty payment to a licensor 68 0 0
Accretion of asset retirement obligation 30 39 146
Amortization of debt discount 0 0 26
Accretion of premium/discount on marketable securities 697 771 511
Changes in operating assets and liabilities:      
Accounts receivable 11,372 (3,583) (8,087)
Inventories 3,186 (1,671) 98
Prepaid expenses and other current assets (3,051) (682) 13
Other assets (1,330) 513 2,814
Accounts payable (6,710) 1,156 (2,105)
Accrued compensation (3,290) (1,322) 1,589
Other accrued liabilities 197 4,351 (6,048)
Deferred revenues (1,789) (4,339) (15,131)
Net cash used in operating activities (11,892) (490) (16,383)
Investing activities:      
Increase in restricted cash 0 (45) (735)
Purchase of property and equipment (2,933) (10,736) (6,990)
Purchase of marketable securities (20,638) (52,564) (49,051)
Purchase of Maxygen patent portfolio 0 0 (20,705)
Proceeds from sale of marketable securities 10,397 6,037 1,605
Proceeds from maturities of marketable securities 29,885 8,500 70,695
Proceeds from disposal of property and equipment 0 0 15
Net cash used in investing activities 16,711 (48,808) (5,166)
Financing activities:      
Principal payments on financing obligations 0 0 (8,026)
Payments in preparation for initial public offering 0 0 (3,870)
Proceeds from issuance of common stock on IPO, net of underwriting discounts 0 0 72,541
Proceeds from exercises of stock options 1,257 2,579 1,594
Net cash provided by financing activities 1,257 2,579 62,239
Effect of exchange rate changes on cash and cash equivalents 165 85 (79)
Net increase (decrease) in cash and cash equivalents 6,241 (46,634) 40,611
Cash and cash equivalents at the beginning of the period 25,762 72,396 31,785
Cash and cash equivalents at the end of the period 32,003 25,762 72,396
Supplemental disclosures of cash flow information:      
Cash paid for interest 0 0 350
Cash paid for income taxes 126 89 336
Supplemental schedule of non-cash investing and financing activities:      
Reclassification of preferred stock warrant from liability to additional paid-in capital $ 0 $ 0 $ 2,686
Conversion of preferred stock to common stock and additional paid-in capital 0 0 179,672